Search results
Results will auto-populate based on filter selection.
Found 938 result(s)
21-02-03
Policy
All claim file information is considered personal information under the Freedom of Information and Protection of Privacy Act (FIPPA) and may be disclosed in…
21-02-05
Policies
All claim file information is considered personal information under The Freedom of Information and Protection of Privacy Act (FIPPA) and may be disclosed…
21-02-04
Policy
All claim file information is considered personal information under The Freedom of Information and Protection of Privacy Act (FIPPA) and may be disclosed in…
21-02-06
Policy
All claim file information is considered personal information under the Freedom of Information and Protection of Privacy Act (FIPPA) and may be disclosed in…
15-04-07
Policy
Where the worker is seriously and permanently disfigured about the face or neck, the WSIB may allow a lump sum in compensation, which is separate and distinct from a…
Update July 26, 2023 The first phase of our consultation began on June 8, 2023 and closed on July 21, 2023. We appreciate all the feedback received, which overwhelmingly…
Each year, we are required under the Workplace Safety and Insurance Act to conduct a value-for-money audit. The latest audit focused on the dispute resolution, appeals and…
12-04-14
Law
s.2(1)
Full-time domestic workers are covered under Schedule 1 of the Act.
Policy
The WSIB provides coverage for domestic workers who are employed more than 24 hours…
On this page: 1. Introduction 1.1. Background 2. Occupational disease legislative and policy scheme…
The Drug Advisory Committee was established in 2007 to guide WSIB on which drugs to include in our drug benefit plan as well as the medical conditions and criteria needed for…
Each year, we are required under the Workplace Safety and Insurance Act (WSIA) to have an external firm review the cost, efficiency, and effectiveness of one of our programs…
Indication(s)The treatment of schizophrenia and related psychotic disorders, manic or mixed episodes in bipolar I disorder, and for use as an adjunct to antidepressants for…
Indication(s)Benzodiazepines are indicated in a treatment of a variety of disorders (depending on their pharmacokinetic profile and evidence), including anxiety disorder,…
Onabotulinumtoxin-A, incobotulinumtoxin-A, abobotulinumtoxin-A Indication(s) OnabotulinumtoxinA (Botox®) is indicated for the treatment of blepharospasm/VII…
Buprenorphine/naloxone (SL), buprenorphine subdermal implant and buprenorphine extended-release (ER) injection Indication(s) Buprenorphine/naloxone sublingual (SL) tablet…
Burpenorphine transdermal patch - butrans® and burprenorphine buccal soluble film belbuca®Indication(s)The management of pain severe enough to require daily, continuous, long…
Indication Prevention of migraine in adults who have at least four migraine days per month. Formulary Status The WSIB Drug Advisory Committee (DAC) recommended that…
Indication(s)Compounded topical analgesics have not been approved by Health Canada and thus have no official indication for the topical treatment of pain.Formulary statusThe…
Corticosteroid injections in musculoskeletal conditions Indications/Clinical uses Treatment of acute and chronic musculoskeletal conditions including neck and upper…
Indication(s)Symptomatic relief of major depressive disorder (MDD).DAC recommendationThe Drug Advisory Committee (DAC) has recommended that desvenlafaxine not be listed on…
Indication (s)Treatment of symptoms associated with osteoarthritis of the knee (duration of treatment not to exceed 3 months).DAC recommendationThe Drug Advisory Committee…
Indication(s)Symptomatic relief of major depressive disorder (MDD), generalized anxiety disorder (GAD), neuropathic pain associated with diabetic peripheral neuropathy (DPN),…
Indication(s)Treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD), and obsessive compulsive disorder (OCD).Formulary statusThe Drug Advisory…